Saturday 17 October 2026
Export SNTI’s income statement to Excel — free account
Senti Biosciences, Inc.
SNTI Healthcare Biotechnology
Senti Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $22,000.00, down 99.1% from fiscal 2023. In the quarter to June 2026, revenue fell 98.7%, EPS grew 26.8% and free cash flow fell 7.48%, each against the same quarter a year earlier.
0.22
0.04
−15.38%
Follow SNTI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
26.19 | 9.74 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(2.40) | (3.35) | — | — | |
P/B ratio |
0.00 | 9.78 | — | — | |
Price to Tangible BV |
0.00 | 9.78 | — | — | |
EV/Sales |
21.28 | 6.28 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(0.73) | (0.44) | — | — | |
EV/FCF |
(0.73) | (0.44) | — | — | |
Quick Ratio |
0.72 | 0.68 | 1.46 | 1.16 | |
Current Ratio |
0.83 | 1.04 | 1.67 | 1.51 | |
Net Debt/EBITDA |
0.47 | 2.27 | 0.92 | 0.76 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.04 | 0.00 | 0.00 | |
Operating CF/Net income |
1.12 | 1.77 | 0.48 | 0.52 | |
Capex/Depreciation |
0.00 | 0.17 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
45,688.24% | 33,006.25% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
39,641.18% | 38,956.25% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6,164.71% | 8,218.75% | 0.00% | 0.00% | |
Graham Net Nets |
(0.69) | (0.83) | — | — | |
Graham Number |
2.09 | 0.00 | — | — | |
Earnings Yield |
(160.91%) | (237.04%) | — | — | |
Free Cash Flow Yield |
(110.73%) | (147.27%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.46) | (0.24) | (0.31) | (0.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.46) | (0.24) | (0.31) | (0.36) | |
Cash per Share |
0.21 | 0.29 | 0.73 | 0.47 | |
Shareholders Equity per Share |
(0.11) | 0.08 | 0.25 | 0.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.11) | 0.08 | 0.25 | 0.31 | |
Free Cash Flow |
(14.25) | (7.37) | (6.87) | (9.45) | |
Working Capital |
(2.76) | 0.52 | 9.30 | 6.13 | |
Capital Expenditures |
0.00 | 0.11 | 0.00 | 0.00 | |
Net Current Asset Value |
(23.50) | (20.89) | (22.36) | (26.41) | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | (7.12) | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
4.31 | 1.49 | 2.87 | 1.47 | |
Average Payables |
1.63 | 1.31 | 2.20 | 1.28 | |
Average Assets |
50.82 | 60.51 | 74.53 | 55.20 | |
Average Common Equity |
10.63 | 20.21 | 15.62 | 12.06 |
Columns are period end dates